RESEARCH AND EXCLUSIVE OPTION AGREEMENTResearch and Exclusive Option Agreement • March 6th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New York
CAMBRIDGE, Mass.—NOV 11, 2014— AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
SECOND AMENDMENT TO LEASELease • March 6th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 13th day of August 2013 (the “Execution Date”), by and between BMR-650 E KENDALL B LLC, a Delaware limited liability company (“Landlord”), and AVEO PHARMACEUTICALS, INC. a Delaware corporation (“Tenant”).
FOURTH AMENDMENT TO LEASELease • March 6th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 1st day of December, 2014, by and between BMR-650 E KENDALL B LLC, a Delaware limited liability company (“Landlord”), and AVEO PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO LEASELease • March 6th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 30th day of April, 2013 (the “Execution Date”), by and between BMR-650 E KENDALL B LLC, a Delaware limited liability company (“Landlord”), and AVEO PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
